This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.
OVERVIEW OF ACTIVITY
Clinical controversies and uncertainties persist in the management of all common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to long-standing clinical questions. As these trials reach maturity, clinical investigators initially present new data in abridged format at large scientific conferences and subsequently in full data sets formally published as part of peer-reviewed journals. Today, numerous annual oncology conferences release new clinical data and hundreds of peer-reviewed publications feature articles related to cancer research, treatment and practical management. The extensive list of available treatment options poses a challenge to the practicing clinician who must maintain knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.
These proceedings from a daylong symposium combine the perspectives of 15 renowned investigators with a review of key recent presentations and publications across breast cancer, gastrointestinal cancers, genitourinary cancers, multiple myeloma, non-small cell lung cancer and Hodgkin and non-Hodgkin lymphoma, including chronic lymphocytic leukemia, to assist medical oncologists and hematologists in the formulation of up-to-date clinical management strategies.
LEARNING OBJECTIVES
- Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, dermatologic and select hematologic cancers.
- Compare and contrast the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
- Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, dermatologic and select hematologic cancers, and refer appropriate patients for study participation.
- Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
- Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
- Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
ACCREDITATION STATEMENT
CME credit is no longer available for this issue
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. The participant should watch the video.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Drs Spigel and Yardley have no real or apparant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
Mark D Pegram, MD
Susy Yuan-Huey Hung Professor of Medicine
Director of the Breast Oncology Program
Co-Director, Translational Oncology Program
Associate Director for Clinical Research
Stanford Cancer Institute
Stanford University School of Medicine
Stanford, California
Consulting Agreements: Celgene Corporation, Cepheid, Genentech BioOncology, Shionogi Inc.
Denise A Yardley, MD
Senior Investigator, Breast Cancer Research
Sarah Cannon Research Institute
Tennessee Oncology, PLLC
Nashville, Tennessee
No financial interests or affiliations to disclose.
Omid Hamid, MD
Chief of Research/Immuno-Oncology
Director of Melanoma Program
The Angeles Clinic and Research Institute
Los Angeles, California
Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Merck; Consulting Agreements: Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Pfizer Inc; Contracted Research: Abbott Laboratories, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Lilly, MedImmune Inc, Merck, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Takeda Oncology; Speakers Bureau: Bristol-Myers Squibb Company, Genentech BioOncology.
David F McDermott, MD
Associate Professor of Medicine
Harvard Medical School
Director, Biologic Therapy and Cutaneous Oncology Programs
Beth Israel Deaconess Medical Center
Leader, Kidney Cancer Program
Dana-Farber Harvard Cancer Center
Boston, Massachusetts
Advisory Committee: Pfizer Inc; Consulting Agreements: Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Roche Laboratories Inc; Contracted Research: Novartis Pharmaceuticals Corporation.
Charles S Fuchs, MD, MPH
Director, Center for Gastrointestinal Cancer
Dana-Farber/Harvard Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Advisory Committee: Acceleron Pharma, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Metamark Genetics Inc, Pfizer Inc, POZEN Inc, Sanofi, Takeda Oncology; Consulting Agreements: Acceleron Pharma, Celgene Corporation, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Metamark Genetics Inc, Pfizer Inc, POZEN Inc, Roche Laboratories Inc, Sanofi, Takeda Oncology.
J Randolph Hecht, MD
Professor of Clinical Medicine
Carol and Saul Rosenzweig Chair in Cancer Therapies Development
Director, UCLA GI Oncology Program
Santa Monica, California
Advisory Committee: Amgen Inc, Genentech BioOncology, Sanofi.
Irene M Ghobrial, MD
Assistant Professor in Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Genzyme Corporation, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.
Joseph Mikhael, MD, MEd
Associate Dean, Mayo School of Graduate Medical Education
Deputy Director - Education, Mayo Clinic Cancer Center
Associate Professor, Mayo College of Medicine
Mayo Clinic in Arizona
Scottsdale, Arizona
Contracted Research: Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi.
David R Spigel, MD
Program Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee
No financial interests or affiliations to disclose.
Heather Wakelee, MD
Associate Professor of Medicine
Division of Oncology
Stanford University School of Medicine
Stanford Cancer Institute
Stanford, California
Consulting Agreements: Peregrine Pharmaceuticals Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Exelixis Inc, Genentech BioOncology, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Xcovery.
Daniel P Petrylak, MD
Professor of Medicine
Director, Prostate and GU Medical Oncology
Co-Director, Signal Transduction Program
Yale Cancer Center
New Haven, Connecticut
Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Corporation, Ferring, Johnson & Johnson Pharmaceuticals, Medivation Inc, Pfizer Inc, Sanofi, Takeda Oncology; Contracted Research: Celgene Corporation, Sanofi, Takeda Oncology; Grant Support: Dendreon Corporation, Johnson & Johnson Pharmaceuticals, OncoGenex Pharmaceuticals Inc, Progenics Pharmaceuticals Inc.
Myron S Czuczman, MD
Chief, Lymphoma/Myeloma Service
Head, Lymphoma Translational Research Laboratory
Roswell Park Cancer Institute
Professor of Medicine
School of Medicine and Biomedical Sciences
State University of New York at Buffalo
Buffalo, New York
Advisory Committee: Algeta ASA, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Gilead Sciences Inc, Mundipharma International Limited, Teva Oncology.
Ian W Flinn, MD, PhD
Director of Blood Cancer Research
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee
Contracted Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Takeda Oncology.
Christopher Flowers, MD, MS
Associate Professor of Hematology and Medical Oncology
Emory School of Medicine Winship Cancer Institute
Atlanta, Georgia
Advisory Committee: Biogen Idec, Genentech BioOncology, Roche Laboratories Inc; Consulting Agreements: Algeta ASA, Celgene Corporation, OptumRx Inc; Contracted Research: Abbott Laboratories, Celgene Corporation, Spectrum Pharmaceuticals Inc, Takeda Oncology.
Craig Moskowitz, MD
Clinical Director, Division of Hematologic Oncology
Attending Physician, Lymphoma and Adult BMT Services
Member, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Medical College of Cornell University
New York, New York
Advisory Committee: Genentech BioOncology, Seattle Genetics; Contracted Research: Genentech BioOncology, GlaxoSmithKline, Merck, Seattle Genetics.
MODERATOR — Dr Love is president and CEO of Research To Practice,
which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Astellas Scientific and Medical Affairs Inc, Bayer HealthCare Pharmaceuticals, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Genentech BioOncology, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Sanofi, Seattle Genetics and Takeda Oncology.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: February 2015
Expiration date: February 2016